NanoNeutVir

Funding: Bundesministerium für Bildung und Forschung (BMBF)

Neutralizing antibodies provide suitable protection against either infection with SARS-CoV-2 virus or at least protection against severe illness e.g. corona virus induced disease 19 (COVID19) and death.

To achieve the desired project aims, different competences are required. Therefore, the project brings together experts from the fields of analytical chemistry, molecular immunology, and virology collaboration with biotech industry to generate a product ready to enter the market. Moreover, this platform can be used in the future to provide a chassis for test assays to detected potent immunity against new emerging virus that might come.

Within the NanoNeutVir consortium, the Wagner Lab is involved in the evolution of those components that provide the liposomes specificity, especially to provide recombinant proteins of RBD variants and ACE2. Moreover, the team will test the efficacy of the established assay with qualified patient sera and benchmark the liposome-based assay against conventional neutralization assays.

Project partners:
University of Regensburg, Institute for Analytical Chemistry – project coordinator
University of Regensburg, Institute for Medical Microbiology and Hygiene, Molecular Microbiology (Virology)
University of Marburg
Microcoat Biotechnology GmbH, Bernried

Further information:
https://www.microcoat.de